ABOUT ZERA MEDICAL

Colorectal cancer is one of the most preventable cancers in the world.¹ The prep is why millions of people are not screened.

Zera Medical was founded to change that.

OUR MISSION

To remove the single greatest barrier to colorectal cancer screening by offering an alternative to the most dreaded part of colonoscopy — a predictable, dignified, clinical-grade preparation experience designed to work consistently.

THE STORY

Why we built ZeraFlow

15M+

COLONSCOPIES PERFORMED ANNUALLY IN U.S.²

30%

COMPROMISED BY INADEQUATE BOWEL PREP³

55%

patients would avoid a future colonoscopy because of bowel prep⁴

More than 15 million colonoscopies are performed in the United States each year. It is the gold standard for preventing colorectal cancer. Yet millions of eligible adults delay or skip screening—not because of the procedure, but because of the preparation.

For decades, patients have been sent home with large volumes of harsh laxatives, complicated instructions, and little clinical support. An uncomfortable, unpredictable process, managed alone. In 30% of cases, that process falls short, leading to compromised procedures, missed lesions, and costly repeat visits.⁵

Zera Medical was built on a simple belief: bowel preparation should not be the patient's responsibility — it should be the care team's. ZeraFlow brings prep into the clinic, under supervision, designed to deliver consistent and reliable preparation quality: A better experience for patients. A better procedure for physicians. A better outcome for everyone.

Several forces are converging at once

  • Two smiling women sit on a park bench, sharing drinks and enjoying the outdoors with a background of trees and people. They are engaged in a friendly conversation, and the scene appears to be in the late afternoon with warm lighting.

    Rising incidence in younger adults

    Colorectal cancer rates are increasing among adults aged 45–55, the fastest-growing screening cohort. Updated guidelines now include patients 45 and older—adding millions who have never experienced prep before.⁶

  • A person wearing a gray T-shirt sitting down and preparing to inject a needle into their arm.

    GLP-1 medications complicate oral prep

    The rapid adoption of GLP-1 medications is making traditional prep less tolerable by slowing gastric emptying. A growing segment of patients now has a medical reason to avoid standard laxative regimens.⁷

  • Close-up of a person typing on a laptop keyboard, with medical tools such as a stethoscope and earphones in the foreground.

    Provider pressure to improve efficiency

    GI practices and ASCs face increasing financial and operational strain from inadequate prep, repeat procedures, and day-of cancellations. ZeraFlow is designed to convert an unpredictable liability into a controlled, revenue-generating clinical step.

  • A nurse showing a clipboard to a man lying in a hospital bed, with a bedside table holding fruit, water, and books, in a medical facility.

    Consumer demand for dignified care

    Patients increasingly expect care that is convenient, comfortable, and modern. The next generation of screening patients has experienced better—and expects it.

ZeraFlow is not available everywhere yet.

We are completing FDA clearance and selecting our first U.S. clinic partners. Enter your information and we will notify you as soon as ZeraFlow is available near you.

¹ Brenner H, Chen C. Br J Cancer. 2018;119(7):785-792. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189126/
² Data Research 2025 / CDC Estimates.
³ Strategies to Improve Inadequate Bowel Preparation for Colonoscopy https://pmc.ncbi.nlm.nih.gov/articles/PMC6857107/
⁴ Vemulapalli KC, Lahr RE, Rex DK. J Clin Gastroenterol. 2023;57(4):400-403. https://pubmed.ncbi.nlm.nih.gov/35324481/
⁵ Ness RM et al. Am J Gastroenterol. 2001;96:1797–1802. https://pubmed.ncbi.nlm.nih.gov/11419832/
⁶ American Cancer Society. Colorectal Cancer Facts & Figures 2023-2025. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2023.pdf
⁷ ASA/AGA/ACG/ASGE/SAGES Multisociety Clinical Practice Guidance for the safe use of GLP-1 receptor agonists prior to endoscopy, 2024. https://www.giejournal.org/article/S0016-5107(24)03591-0/abstract